



JUNE 30<sup>th</sup>, 2022  
1:00 pm CEST

## CLINICAL EXPERIENCE WITH BIOBETTERS IN IBD

Biosimilars are increasingly used to treat patients with IMIDs. Biobetters have changed the way oncology patients are treated. Biobetters may be associated with improvements in clinical outcomes and drug pharmacology. The first anti-TNF biobetter was recently approved for IBD. What is a biobetter? What is the current level of evidence in IBD? What are the indications of biobetters in IBD? These questions will be answered during this interactive webinar.

### FACULTY

**Silvio Danese**

Professor of Gastroenterology,  
Head of Gastroenterology and Endoscopy  
San Raffaele Hospital, Milan, Italy

**Axel Dignass**

Head of the Department of Medicine I and Professor  
of Medicine and Gastroenterology at the Agaplesion  
Markus Hospital - Frankfurt am Main, Germany

**Benedicte Caron**

Department of Gastroenterology,  
Université de Lorraine, Nancy, France

**Laurent Peyrin-Biroulet**

Full Professor of Medicine IBD Unit  
Department of Gastroenterology Nancy  
University Hospital, France

**Mathurin Fumery**

Gastroenterology Unit, Peritox UMR I-01,  
Amiens University and Hospital,  
Université de Picardie Jules Verne, Amiens, France

*Chairs: Silvio Danese, Italy  
Axel Dignass, Germany*

**Intro**

Silvio Danese, *Italy*  
Axel Dignass, *Germany*

**When to initiate? Clinical cases 15'**

Benedicte Caron, *France*

**When to switch? Clinical cases 15'**

Laurent Peyrin-Biroulet, *France*

**Experience with biobetters in case  
of previous IV Infliximab failure 15'**

Mathurin Fumery, *France*

**Q&A 10'**

[CLICK HERE  
TO REGISTER](#)

Sponsored by



ORGANIZATION OFFICE  
Materia Prima srl  
segreteria@materia1a.it | materia1a.it  
ibdscope@ibdscope.com